HPTX Stock News 25.92 05/13/2014 17:59:47 Hyperion Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Hyperion Therapeutics Inc (HPTX) 25.92 $HPTX

Hyperion Therapeutics to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 3:47PM CDT
Hyperion Therapeutics (Nasdaq:HPTX) today announced that the company is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014, at 1:40 p.m. PT.

Hyperion Therapeutics Announces First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
- Company signs definitive agreement to expand its pipeline -

The Zacks Analyst Blog Highlights: Gilead, Acorda Therapeutics, Hyperion Therapeutics and Medivation
PR Newswire - Fri May 02, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead (Nasdaq:GILD-Free Report), Acorda Therapeutics, Inc. (Nasdaq:ACOR-Free Report), Hyperion Therapeutics, Inc. (Nasdaq:HPTX-Free Report) and Medivation, Inc. (Nasdaq:MDVN-Free Report).

3 Biotech Beats this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu May 01, 11:01AM CDT
Things have been looking up for the biotech industry since last week

Why the Earnings Streak Will Continue for Hyperion Therapeutics (HPTX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:50AM CDT
Hyperion Therapeutics may be a great candidate for another beat, as it has seen a streak of beating earnings estimates at the previous two reports

Why Earnings Season Could Be Great for Hyperion Therapeutics (HPTX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:45AM CDT
Hyperion Therapeutics has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front

Hyperion Therapeutics to Report First Quarter 2014 Financial Results After Market on May 6, 2014
GlobeNewswire - Wed Apr 30, 8:00AM CDT
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report first quarter 2014 financial results after market close on Tuesday, May 6, 2014. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

Hyperion Set to Acquire Andromeda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:58PM CDT
Hyperion entered into a definitive agreement to acquire Andromeda Biotech Ltd. for $12.5 million in cash and 312,869 in Hyperion shares.

Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd.
GlobeNewswire - Thu Apr 24, 2:30AM CDT
--DiaPep277, a First-in-Class Immune Intervention Therapy in

Hyperion Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 3:14PM CDT
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 13 Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 10:00 a.m. ET.

Hyperion Therapeutics to Present at the 26th Annual Roth Conference
GlobeNewswire - Fri Mar 07, 9:23AM CST
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 26 Annual Roth Conference on Tuesday, March 11, 2014 at 10:30 a.m. PT.

Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.

AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.

This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 2:15PM CST
With the  SPDR S&P Biotech Index  up  75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Hyperion Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Feb 27, 3:13PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $18.6 million and $42.2 million for the fourth quarter and full year 2013, respectively. Hyperion's revenues are for sales of its two products for the treatment of urea cycle disorders, RAVICTI (glycerol phenylbutyrate) Oral Liquid, launched on March 1, 2013 and BUPHENYL (sodium phenylbutyrate) Tablets and Powder acquired on May 31, 2013. Adjusted net income for the fourth quarter 2013 was $4.1 million compared to an adjusted net loss of $7.9 million in the fourth quarter of 2012, an increase in net income of $12.0 million. The company ended 2013 with cash, cash equivalents and investments of $118.1 million, an increase of $9.5 million from the prior quarter.

Hyperion Therapeutics to Present at the Cowen and Company 34th Annual Healthcare Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Cowen and Company 34 Annual Healthcare Conference on Monday, March 3 at 2:50 p.m. ET.

Why Hyperion Therapeutics Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 12:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Hyperion Therapeutics , a...

Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 12:28PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology
GlobeNewswire - Tue Feb 25, 9:25AM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the March 2014 issue of Hepatology. The study met its primary endpoint with significantly fewer patients treated with GPB experiencing HE events as compared to patients receiving placebo.

Zhejiang Giuseppe Garment Digs for New Customers
SinoCast - Tue Feb 25, 4:54AM CST
Zhejiang Giuseppe Garment Co., Ltd. (SZSE: 002687) revealed declining sales revenue affected by dim garment market situation in 2013. Hence, the company planned to extend customers from finance, power, and tobacco to private school and government fields.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

ParagonX Holdings: Update on Company Transformation Plans

Updated Category News Views 146

ParagonX Holdings Shareholder Update ParagonX Holdings, Inc. (OTC:CAVR) recently shared insightful information regarding its transformation and strategic direction. The company is under the management of Caprino Management, LLC, which is actively assessing acquisition opportunities to bolster its growth. Divestitures and Debt Restructuring A significant step taken by...

Continue Reading
Applaud Receives Prestigious AI Award for Transforming HR

Updated Category News Views 300

Applaud Triumphs with Prestigious AI Award Applaud, a leading innovator in HR technology, has achieved significant recognition in the tech industry. The company’s generative-AI HR platform was awarded the flagship AI Award at a major international event. Applaud was selected among several finalists, showcasing its commitment to providing measurable value to employees...

Continue Reading
Empowering Stories: A Mother's Journey to a New Start

Updated Category News Views 257

Empowering Stories: A Mother's Journey to a New Start Anita's story is one of resilience. Faced with overwhelming challenges in her early life, she fought tirelessly to change her circumstances. Growing up without a family, she was married at a tender age to an older man, and for years, she juggled the responsibilities of motherhood while tending to her husband’s...

Continue Reading
First Capital REIT Declares Monthly Distribution for Investors

Updated Category News Views 176

First Capital REIT Announces Distribution for October 2025 First Capital REIT announces its cash distribution for October 2025, setting a notable precedent for its unitholders. The company has declared a distribution of $0.074167 per REIT unit, which translates to an annualized payout of $0.89 per unit. The payment is scheduled for November 17, 2025, to unitholders...

Continue Reading
Sidus Space and Other Major Stocks Experience Declines

Updated Category News Views 166

Stock Market Dynamics: Sidus Space and Others The U.S. stock market is seeing some fluctuations as futures showed little movement earlier today. Among these movements, Nasdaq 100 futures gently slipped by about 0.01%. In the midst of this, shares of Sidus Space, Inc. (NASDAQ: SIDU) are particularly noteworthy. Sidus Space's Price Adjustment Sidus Space recently made...

Continue Reading